Autoimmune disease treatment stories

Jul 27, 2026

Argenx to Acquire Forte Biosciences for $2.2 Billion to Expand Immunology Portfolio

Belgian-Dutch biotech argenx agreed to acquire Forte Biosciences for $2.2 billion in cash ($77 per share, an 86% premium to its VWAP since July 9), adding FB102, an anti-CD122 antibody in development for vitiligo and celiac disease, to its immunology pipeline.

Jul 27, 2026·4 sources

Jul 7, 2026

FDA Approves Vera Therapeutics' TRUTAKNA for IgA Nephropathy Treatment

The U.S. Food and Drug Administration has granted accelerated approval to Vera Therapeutics' drug TRUTAKNA for treating adult patients with primary IgA nephropathy, a potentially life-threatening chronic autoimmune kidney disease. The approval sent Vera's shares up 6.8% in afternoon trading.

Jul 7, 2026·3 sources

May 5, 2026

UCB Acquires Maker of Antibody Treatments for Autoimmune Diseases

Belgian pharmaceutical company UCB has announced the acquisition of a company specializing in antibody treatments for autoimmune diseases, expanding its immunology portfolio.

May 5, 2026·1 source

Top claims

▪The $77 per share offer represents an approximate 86% premium to Forte Biosciences Inc.'s volume-weighted average price since July 9, 2026.
▪The acquisition is subject to customary closing conditions and regulatory approvals, but is not subject to a financing condition.
▪The acquisition is expected to close in the third quarter of 2026.

Subtopics

FDA drug approval Pharmaceutical Industry

Related timelines

Autoimmune disease treatment stories

Argenx to Acquire Forte Biosciences for $2.2 Billion to Expand Immunology Portfolio

FDA Approves Vera Therapeutics' TRUTAKNA for IgA Nephropathy Treatment

UCB Acquires Maker of Antibody Treatments for Autoimmune Diseases

Related timelines

US Congress

Venture capital funding

Iran War

Strait of Hormuz blockage

Trump administration